IGM’s autoimmune pivot backfires as top drug disappoints in ...
3 days ago · IGM Biosciences will scrap its top two drugs and lay off nearly three-quarters of its workforce after reporting study results that fell short of the company’s expectations. In an announcement Thursday , IGM said it halted development of experimental therapies known as imvotamab and IGM-2644 that were being tested in autoimmune conditions.
IMG Biosciences enacts massive lay-offs after Phase I trial ...
1 day ago · California-based biotech, IGM Biosciences, has put a halt to the development of two of its autoimmune disease therapies, imvotamab and IGM-2644, after Phase I trials saw disappointing results ...
IGM Biosciences Halts Antibody Therapies, Cuts Workforce
1 day ago · IGM Biosciences ( ) just unveiled an update. IGM Biosciences announced a strategic update to halt the development of two antibody therapies, imvotamab and IGM-2644, for autoimmune diseases due to ...
IGM Biosciences Lays Off 73% of Staff, Shrinks Pipeline
1 day ago · IGM Biosciences is cutting 73% of its workforce and stopping development of two autoimmune drug candidates, the biotech announced Jan. 9. Following the news, BMO Capital Markets downgraded the Mountain View, California–based company’s shares from …
IGM Biosciences Halts Development of Imvotamab and ... - Nasdaq
2 days ago · IGM Biosciences halts imvotamab and IGM-2644 development, reducing workforce by 73% amid cash preservation efforts. Quiver AI Summary. IGM Biosciences, Inc. is halting the development of its ...
IGM Biosciences Halts Development of Two Investigational ...
1 day ago · IGM Biosciences announced they are halting the development of two investigational drugs for autoimmune and inflammatory diseases, imvotamab (an IgM-based CD20 X CD3 bispecific antibody T cell engager) and IGM-2644 (an IgM-based CD38 X CD3 bispecific antibody T cell engager). Interim data from the ...
IGM Biosciences to cut 73% of workforce as latest pivot fails ...
IGM Biosciences Inc. said Thursday it is cutting 73% of its workforce after deciding to halt further development of a program relating to its autoimmunity-drug pipeline, sending its stock down 69% ...
Top 1% Biotech, IGM Biosciences, Plummets On Scrapped Drug, C ...
Oct 1, 2024 · IGM Biosciences (IGMS) is developing imvotamab as a treatment for rheumatoid arthritis and systemic lupus erythematosus. In the shift, IGM is winding down efforts to develop aplitabart, a...
IGM Biosciences to Halt Development of Imvotamab, Cut 73% of ...
3 days ago · By Chris Wack. IGM Biosciences has decided to halt development of imvotamab and IGM-2644, two IgM-based bispecific antibody T cell engagers for autoimmune diseases, and cut its staff by 73%.
IGM Biosciences Provides Strategic Update on Autoimmunity
2 days ago · – Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited ...
- Some results have been removed